FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056547838> ?p ?o ?g. }

• W2056547838 endingPage "987" @default.
• W2056547838 startingPage "986" @default.
• W2056547838 abstract "To the Editor: GlaxoSmithKline regrets the recommendation [1] of the recent consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes against the use of rosiglitazone for treatment of type 2 diabetes, because it is contrary to scientific evidence. The evidence regarding a possible association of rosiglitazone with increased risk of cardiovascular ischaemic morbidity remains inconclusive. Data from clinical trials assessing cardiovascular outcomes are inconsistent with hypotheses of increases in the rates of myocardial ischaemia or death that have arisen from meta-analyses. No long-term clinical trial has confirmed an increased risk of cardiovascular ischaemia with rosiglitazone. Moreover, data from two large head-to-head clinical trials—A Diabetes Outcome Progression Trial (ADOPT) [2] and the interim report of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) trial [3]— show that, apart from the well-documented risk of heart failure with thiazolidinediones, rosiglitazone has a cardiovascular risk profile comparable to the recommended tier 1 glucose-lowering medicines, metformin and sulfonylurea. The consensus statement contains multiple unexplained inconsistencies regarding the evidence underlying its conclusions and recommendations. Data from long-term clinical trials, which provide gold-standard evidence, sometimes appear to receive less weight than conclusions from hypothesisgenerating meta-analyses. This circumstance is difficult to understand, particularly in light of a recent comment by the corresponding author of the consensus statement [4] that ‘the vagaries of meta-analyses make them unreliable’. Furthermore, the consensus statement cites data in an inconsistent manner. Meta-analyses critical of rosiglitazone are mentioned repeatedly, while analyses reporting no increase in cardiovascular ischaemic risk with rosiglitazone versus other established glucose-lowering medications are overlooked (such as those performed by Lago et al. [5] and the US Food and Drug Administration [FDA] [6]). A metaanalysis [7] that reported a statistically significant increase in a composite endpoint of cardiovascular hospitalisation or mortality with the combination of sulfonylureas and metformin—a tier 1 recommended option—is not mentioned in the consensus statement. The authors of the consensus statement write that ‘the overarching principle in selecting a particular intervention will be its ability to achieve and maintain glycaemic goals’ [1]. Rosiglitazone has been shown to provide glycaemic control for up to 5 years—significantly longer than the most commonly used oral glucose-lowering medications, sulfonylurea and metformin [2]. GlaxoSmithKline strongly believes that rosiglitazone has a place in the therapeutic armamentarium for type 2 diabetes when used appropriately. Diabetologia (2009) 52:986–987 DOI 10.1007/s00125-009-1301-3" @default.
• W2056547838 created "2016-06-24" @default.
• W2056547838 creator A5014367124 @default.
• W2056547838 creator A5091070939 @default.
• W2056547838 date "2009-03-04" @default.
• W2056547838 modified "2023-09-25" @default.
• W2056547838 title "GlaxoSmithKline responds to the consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes" @default.
• W2056547838 cites W1972136146 @default.
• W2056547838 cites W2081041757 @default.
• W2056547838 cites W2081276121 @default.
• W2056547838 cites W2095784604 @default.
• W2056547838 cites W2105407506 @default.
• W2056547838 cites W2139562487 @default.
• W2056547838 doi "https://doi.org/10.1007/s00125-009-1301-3" @default.
• W2056547838 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19259643" @default.
• W2056547838 hasPublicationYear "2009" @default.
• W2056547838 type Work @default.
• W2056547838 sameAs 2056547838 @default.
• W2056547838 citedByCount "1" @default.
• W2056547838 crossrefType "journal-article" @default.
• W2056547838 hasAuthorship W2056547838A5014367124 @default.
• W2056547838 hasAuthorship W2056547838A5091070939 @default.
• W2056547838 hasBestOaLocation W20565478381 @default.
• W2056547838 hasConcept C126322002 @default.
• W2056547838 hasConcept C134018914 @default.
• W2056547838 hasConcept C142853389 @default.
• W2056547838 hasConcept C15744967 @default.
• W2056547838 hasConcept C17744445 @default.
• W2056547838 hasConcept C199539241 @default.
• W2056547838 hasConcept C2777026412 @default.
• W2056547838 hasConcept C2986265897 @default.
• W2056547838 hasConcept C542102704 @default.
• W2056547838 hasConcept C555293320 @default.
• W2056547838 hasConcept C71924100 @default.
• W2056547838 hasConceptScore W2056547838C126322002 @default.
• W2056547838 hasConceptScore W2056547838C134018914 @default.
• W2056547838 hasConceptScore W2056547838C142853389 @default.
• W2056547838 hasConceptScore W2056547838C15744967 @default.
• W2056547838 hasConceptScore W2056547838C17744445 @default.
• W2056547838 hasConceptScore W2056547838C199539241 @default.
• W2056547838 hasConceptScore W2056547838C2777026412 @default.
• W2056547838 hasConceptScore W2056547838C2986265897 @default.
• W2056547838 hasConceptScore W2056547838C542102704 @default.
• W2056547838 hasConceptScore W2056547838C555293320 @default.
• W2056547838 hasConceptScore W2056547838C71924100 @default.
• W2056547838 hasIssue "5" @default.
• W2056547838 hasLocation W20565478381 @default.
• W2056547838 hasLocation W20565478382 @default.
• W2056547838 hasOpenAccess W2056547838 @default.
• W2056547838 hasPrimaryLocation W20565478381 @default.
• W2056547838 hasRelatedWork W1563850031 @default.
• W2056547838 hasRelatedWork W2233866314 @default.
• W2056547838 hasRelatedWork W2314213174 @default.
• W2056547838 hasRelatedWork W2415759662 @default.
• W2056547838 hasRelatedWork W2509026208 @default.
• W2056547838 hasRelatedWork W3036934084 @default.
• W2056547838 hasRelatedWork W4214901303 @default.
• W2056547838 hasRelatedWork W4232275348 @default.
• W2056547838 hasRelatedWork W4248795736 @default.
• W2056547838 hasRelatedWork W4298378311 @default.
• W2056547838 hasVolume "52" @default.
• W2056547838 isParatext "false" @default.
• W2056547838 isRetracted "false" @default.
• W2056547838 magId "2056547838" @default.
• W2056547838 workType "article" @default.